Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

STRONG Trial - Stem Cell Radiotherapy (ScRT) and Temozolomide for Newly Diagnosed High-grade Glioma (HGG): A Prospective, Phase I/II Trial

NCT02039778 is registered in ClinicalTrials.gov with Beth Israel Medical Center as lead sponsor.

NCT NCT02039778
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02039778 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
STRONG Trial - Stem Cell Radiotherapy (ScRT) and Temozolomide for Newly Diagnosed High-grade Glioma (HGG): A Prospective, Phase I/II Trial
Lead sponsor
Beth Israel Medical Center
Phase
Not applicable
Overall status
Terminated
Start date
December 31, 2013
Completion date
December 31, 2015
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, brain tumors, glioblastoma, malignant glioma